Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1787 • ACR Convergence 2020
Differences in Chromatin Architecture Between Treatment Naïve Pediatric and Adult Lupus Patients
Joyce Hui-Yuen¹, Frank Jenkins², Kaiyu Jiang³, Susan Malkiel⁴, Betty Diamond⁴ and James Jarvis⁵, ¹Northwell LIJ Health System, Manhasset, NY, ²Northwell Health, Manhasset, ³University at Buffalo, Buffalo, NY, ⁴Northwell Health, Manhasset, NY, ⁵University at Buffalo Jacobs School of Medicine, Buffalo, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is possibly triggered by gene-environment interactions. We showed most of the SLE haplotypes encompass genomic regions enriched for epigenetic marks…
Abstract Number: 1806 • ACR Convergence 2020
The Association of Interferon-α with Kynurenine/Tryptophan Pathway Activation in Systemic Lupus Erythematosus
Erik Anderson¹, Ying Jin², Sara Goodwin², Julien Roeser³, Richard Furie⁴, Cynthia Aranow⁵, Bruce Volpe⁵, Betty Diamond⁶ and Meggan Mackay⁷, ¹Feinstein Institutes for Medical Research, New York, NY, ²Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, ³Charles River Laboratories, South San Francisco, CA, ⁴Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁵Feinstein Institutes for Medical Research, Manhasset, NY, ⁶Northwell Health, Manhasset, NY, ⁷Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: Type I IFN contributes to SLE pathogenesis and stimulates the kynurenine/tryptophan (KYN/TRP) pathway, producing elevated quinolinic acid (QA) levels relative to kynurenic acid (KA)…
Abstract Number: 1823 • ACR Convergence 2020
Mycophenolate Mofetil for Systemic Lupus Erythematosus: Our 20-year Experience
Michael Trevisonno¹, Alexander Hall¹, Cristina Sorrento¹ and Ellen M Ginzler², ¹State University of New York Downstate Medical Center, Brooklyn, NY, ²SUNY Downstate Health Sciences University, Brooklyn
Background/Purpose: Mycophenolate Mofetil (MMF) has been long used in the treatment of systemic lupus Erythematosus (SLE). Despite its proven effectiveness, particularly in the treatment of…
Abstract Number: 1840 • ACR Convergence 2020
A Novel Biomarker Identifies Systemic Lupus Erythematous (SLE) Patients Who Benefit from Obexelimab (XmAb®5871) Treatment
Ying Ding¹, Debra Zack¹, Bart Burington¹, Allen Yang¹, Joan Merrill², Judith James³, John Desjarlais¹, Raphael Clynes¹ and Joel Guthridge⁴, ¹Xencor Inc, Monrovia, CA, ²New York University, New York, ³Oklahoma Medical Research Foundation, Oklahoma City, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: We previously reported Phase 2 SLE trial results for obexelimab, a CD19-targeted FcγRIIb engager that suppresses B-cell activation [1]. The primary endpoint, which measured…
Abstract Number: 0243 • ACR Convergence 2020
The Role of Anti-dsDNA Antibodies in Predicting Incident Lupus Nephritis in Newly Diagnosed Lupus
Pooja Kumari¹, Viswanathan Ramakrishnan², Jihad Obeid², Diane Kamen³ and Jim Oates⁴, ¹The university of Tennesse Health Science center, Memphis, TN, ²medical university of south carolina, south carolina, ³Medical University of South Carolina, Charleston, SC, ⁴Medical University of South Carolina, Charleston, SC, Charleston, SC
Background/Purpose: Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus (SLE) that leads to significant morbidity and mortality. Therefore, it is essential to…
Abstract Number: 0259 • ACR Convergence 2020
Guillain-Barré Syndrome in Systemic Lupus Erythematosus – Results of a Nationwide Analysis
Shilpa Arora¹, Ehizogie Edigin² and Augustine Manadan¹, ¹Rush University Medical Center, Chicago, IL, ²John H Jr. Stroger Hospital of Cook County, Chicago, IL
Background/Purpose: Guillain-Barré Syndrome (GBS) is a rare autoimmune polyneuropathy well described following viral illness, vaccination, or surgery. Systemic Lupus Erythematosus (SLE) has been associated with several…
Abstract Number: 0276 • ACR Convergence 2020
Type 2 SLE Symptoms Persist Despite Type 2 Medication Polypharmacy
Raeann Whitney¹, Amanda Eudy², Cynthia Coffman³, Megan Clowse⁴, Lisa Criscione-Schreiber⁵, Jayanth Doss², Rebecca Sadun², Kai Sun² and Jennifer Rogers⁶, ¹Duke University Medical Center, Durham, NC, ²Duke University, Durham, NC, ³Duke University, Durham, ⁴Duke University, Chapel Hill, NC, ⁵Duke University School of Medicine, Durham, NC, ⁶Duke, Durham, NC
Background/Purpose: Management of Type 2 SLE (widespread pain, fatigue, depression, sleep distrubance, and cognitive dysfunction) is challenging and often requires multiple medications to ameliorate symptoms.…
Abstract Number: 0294 • ACR Convergence 2020
Tired T-Cells and Monocytes with Malaise: Investigating the Links Between Cellular Iron Deficiency and Mitochondrial Dysfunction in Systemic Lupus Erythematosus
Chris Wincup¹, Thomas McDonnell¹, George Robinson², Filipa Farinha¹, Anna Radziszewska¹ and Anisur Rahman¹, ¹University College London, London, United Kingdom, ²University College London, Hertford, United Kingdom
Background/Purpose: Iron is vital for many physiological processes and is found within respiratory complexes of the mitochondrial electron transport chain, the key site of oxidative phosphorylation…
Abstract Number: 0439 • ACR Convergence 2020
Hurried Communication and Low Patient Self-Efficacy Are Associated with Persistent Non-Adherence to SLE Medications
Ann Cameron Barr¹, Megan Clowse², Amanda Eudy³, Jennifer Rogers⁴, Rebecca Sadun³, Lisa Criscione-Schreiber⁵, Jayanth Doss³, Lena Eder⁶, Mithu Maheswaranathan³, Amy Corneli⁷, Hayden Bosworth⁷ and Kai Sun³, ¹Duke University Hospital, Durham, NC, ²Duke University, Chapel Hill, NC, ³Duke University, Durham, NC, ⁴Duke, Durham, NC, ⁵Duke University School of Medicine, Durham, NC, ⁶Duke University Hospital, Chapel Hill, NC, ⁷Duke University, Durham
Background/Purpose: Medication non-adherence is common among SLE patients and contributes to poor outcomes. Underrepresented racial minorities have disproportionately lower rates of medication adherence and often…
Abstract Number: 0577 • ACR Convergence 2020
Qualitative Review of Unsuccessful Pilot Study of Super-Utilizer Systemic Lupus Erythematosus (SLE) Patients Enrollment into Team Based Program to Improve Patient Outcomes
Sarah Min¹, Devy Setyono², Sunghye Kim³, Feben Girma¹, Melanie Martin¹ and Rachel Wolfe¹, ¹Wake Forest Baptist Medical Center, Winston-Salem, NC, ²Emkey Arthritis and Osteoporosis Clinic, Wyomissing, PA, ³W.G. Hefner VA Medical Center, Salisbury, NC
Background/Purpose: SLE is a chronic multi-system autoimmune disease, affecting mostly women of child-bearing age and more racial minorities, with a wide spectrum of outcomes: from…
Abstract Number: 0843 • ACR Convergence 2020
Rab4A Activation Predisposes to Hepatitis in Spontaneous and Pristane-Induced Mouse Models of Systemic Lupus Erythematosus
Nick Huang¹, Akshay Patel¹, Zachary Oaks¹ and Andras Perl¹, ¹SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: HRES-1/Rab4 or Rab4A, a GTPase responsible for mitochondrial oxidative stress1 and activation of the mechanistic target of rapamycin2, is overexpressed in T cells of…
Abstract Number: 0862 • ACR Convergence 2020
Voclosporin Does Not Decrease Mycophenolic Acid Concentrations in Patients with SLE
Teun van Gelder¹, Robert Huizinga², Neil Solomons² and Laura Lisk³, ¹Leiden University Medical Centre, Leiden, Zuid-Holland, Netherlands, ²Aurinia Pharmaceuticals, Victoria, BC, Canada, ³Aurinia Pharmaceuticals Inc., Victoria, BC, Canada
Background/Purpose: Voclosporin (VCS) is a novel calcineurin inhibitor, structurally similar to cyclosporine A (CsA). In a Phase 3 clinical trial in patients with active lupus…
Abstract Number: 0976 • ACR Convergence 2020
Kidney-infiltrating T Cells in Murine Lupus Nephritis Exhibit Transcriptional Heterogeneity and Oligoclonal Expansion
Shuchi Smita¹, Minjung Kim¹, Maria Chikina¹, Mark Shlomchik¹ and Jeremy Tilstra¹, ¹University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Lupus nephritis (LN) is a hallmark of SLE, affecting 50-60% of patients within 10 years of diagnosis. Current treatments for LN have suboptimal response…
Abstract Number: 1022 • ACR Convergence 2020
Declining In-hospital Mortality Gap in Lupus Compared to Non-lupus Hospitalizations: A National Study
Jasvinder Singh¹ and John Cleveland¹, ¹University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Lupus is a serious, multi-system autoimmune disease that affects young people. Mortality is increased by over 2-3 fold compared to the general population. Time-trends…
Abstract Number: 1259 • ACR Convergence 2020
The Impact of Antimalarial Agents on Traditional and Non-traditional Cardiovascular Markers in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis
Claudia Mendoza-Pinto¹, Mario Garcia-Carrasco¹, Pamela Munguía-Realpozo², Ivet Etchegaray-Morales² and Socorro Mendez-Martínez¹, ¹Instituto Mexicano del Seguro Social, Puebla, Puebla, Mexico, ²Facultad de Medicina, Benemérita Universidad Autónoma de Puebla, Puebla, Puebla, Mexico
Background/Purpose: Cardiovascular morbidity and mortality is a well-established problem in patients with systemic lupus erythematosus (SLE). Hydroxychloroquine (HCQ) has been seen as a potential atheroprotective…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].